Literature DB >> 15964799

Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus.

Christopher C Valley1, Raphaël Métivier, Natalia M Solodin, Amy M Fowler, Mara T Mashek, Lindsay Hill, Elaine T Alarid.   

Abstract

The ubiquitin-proteasome pathway has emerged as an important regulatory mechanism governing the activity of several transcription factors. While estrogen receptor alpha (ERalpha) is also subjected to rapid ubiquitin-proteasome degradation, the relationship between proteolysis and transcriptional regulation is incompletely understood. Based on studies primarily focusing on the C-terminal ligand-binding and AF-2 transactivation domains, an assembly of an active transcriptional complex has been proposed to signal ERalpha proteolysis that is in turn necessary for its transcriptional activity. Here, we investigated the role of other regions of ERalpha and identified S118 within the N-terminal AF-1 transactivation domain as an additional element for regulating estrogen-induced ubiquitination and degradation of ERalpha. Significantly, different S118 mutants revealed that degradation and transcriptional activity of ERalpha are mechanistically separable functions of ERalpha. We find that proteolysis of ERalpha correlates with the ability of ERalpha mutants to recruit specific ubiquitin ligases regardless of the recruitment of other transcription-related factors to endogenous model target genes. Thus, our findings indicate that the AF-1 domain performs a previously unrecognized and important role in controlling ligand-induced receptor degradation which permits the uncoupling of estrogen-regulated ERalpha proteolysis and transcription.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964799      PMCID: PMC1156995          DOI: 10.1128/MCB.25.13.5417-5428.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

1.  Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription.

Authors:  J J Watters; J S Campbell; M J Cunningham; E G Krebs; D M Dorsa
Journal:  Endocrinology       Date:  1997-09       Impact factor: 4.736

2.  The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily.

Authors:  Z Nawaz; D M Lonard; C L Smith; E Lev-Lehman; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells.

Authors:  S Miyamoto; B J Seufzer; S D Shumway
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

4.  Molecular basis of agonism and antagonism in the oestrogen receptor.

Authors:  A M Brzozowski; A C Pike; Z Dauter; R E Hubbard; T Bonn; O Engström; L Ohman; G L Greene; J A Gustafsson; M Carlquist
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

5.  Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation.

Authors:  E Castaño; D P Vorojeikina; A C Notides
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

6.  Protein synthesis is not implicated in the ligand-dependent activation of the estrogen receptor in MCF-7 cells.

Authors:  A El Khissiin; A Cleeren; M Borràs; G Leclercq
Journal:  J Steroid Biochem Mol Biol       Date:  1997-07       Impact factor: 4.292

7.  Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling.

Authors:  George Reid; Michael R Hübner; Raphaël Métivier; Heike Brand; Stefanie Denger; Dominique Manu; Joël Beaudouin; Jan Ellenberg; Frank Gannon
Journal:  Mol Cell       Date:  2003-03       Impact factor: 17.970

8.  pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167.

Authors:  P B Joel; J Smith; T W Sturgill; T L Fisher; J Blenis; D A Lannigan
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

9.  Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR.

Authors:  H Masuyama; P N MacDonald
Journal:  J Cell Biochem       Date:  1998-12-01       Impact factor: 4.429

10.  Identification of the gal4 suppressor Sug1 as a subunit of the yeast 26S proteasome.

Authors:  D M Rubin; O Coux; I Wefes; C Hengartner; R A Young; A L Goldberg; D Finley
Journal:  Nature       Date:  1996-02-15       Impact factor: 49.962

View more
  53 in total

1.  Turning off estrogen receptor beta-mediated transcription requires estrogen-dependent receptor proteolysis.

Authors:  Yukiyo Tateishi; Raku Sonoo; Yu-ichi Sekiya; Nanae Sunahara; Miwako Kawano; Mitsutoshi Wayama; Ryuichi Hirota; Yoh-ichi Kawabe; Akiko Murayama; Shigeaki Kato; Keiji Kimura; Junn Yanagisawa
Journal:  Mol Cell Biol       Date:  2006-08-28       Impact factor: 4.272

2.  Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1.

Authors:  Prashant Rajbhandari; Greg Finn; Natalia M Solodin; Kiran K Singarapu; Sarata C Sahu; John L Markley; Kelley J Kadunc; Stephanie J Ellison-Zelski; Anastasia Kariagina; Sandra Z Haslam; Kun Ping Lu; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

Review 3.  Transcription in four dimensions: nuclear receptor-directed initiation of gene expression.

Authors:  Raphaël Métivier; George Reid; Frank Gannon
Journal:  EMBO Rep       Date:  2006-02       Impact factor: 8.807

4.  The 19 s proteasome subcomplex establishes a specific protein interaction network at the promoter for stimulated transcriptional initiation in vivo.

Authors:  Shivani Malik; Abhijit Shukla; Payel Sen; Sukesh R Bhaumik
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

5.  ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.

Authors:  Hetal Patel; Manikandan Periyasamy; Georgina P Sava; Alexander Bondke; Brian W Slafer; Sebastian H B Kroll; Marion Barbazanges; Richard Starkey; Silvia Ottaviani; Alison Harrod; Eric O Aboagye; Laki Buluwela; Matthew J Fuchter; Anthony G M Barrett; R Charles Coombes; Simak Ali
Journal:  Mol Cancer Ther       Date:  2018-03-15       Impact factor: 6.261

6.  Chromatin context dominates estrogen regulation of pS2 gene expression.

Authors:  Akua K Oduro; Michael K Fritsch; Fern E Murdoch
Journal:  Exp Cell Res       Date:  2008-07-15       Impact factor: 3.905

7.  The Phosphorylated Estrogen Receptor α (ER) Cistrome Identifies a Subset of Active Enhancers Enriched for Direct ER-DNA Binding and the Transcription Factor GRHL2.

Authors:  Kyle T Helzer; Mary Szatkowski Ozers; Mark B Meyer; Nancy A Benkusky; Natalia Solodin; Rebecca M Reese; Christopher L Warren; J Wesley Pike; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2019-01-16       Impact factor: 4.272

8.  A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Authors:  Dan Tian; Natalia M Solodin; Prashant Rajbhandari; Kelsi Bjorklund; Elaine T Alarid; Pamela K Kreeger
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

9.  Blockade of estrogen action upregulates estrogen receptor-alpha mRNA in the fetal brain.

Authors:  Christine E Schaub; Charles E Wood
Journal:  Neonatology       Date:  2009-03-12       Impact factor: 4.035

10.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.